Consider TLR5 for new therapeutic development against COVID-19.
作者信息
Chakraborty Chiranjib, Sharma Ashish Ranjan, Bhattacharya Manojit, Sharma Garima, Lee Sang-Soo, Agoramoorthy Govindasamy
机构信息
Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India.
Institute for Skeletal Ageing and Orthopedic Surgery, Hallym University Chuncheon sacred Heart Hospital, Chuncheon-si, Gangwon-do, Korea.
出版信息
J Med Virol. 2020 Nov;92(11):2314-2315. doi: 10.1002/jmv.25997. Epub 2020 May 22.
Abstract
摘要
相似文献
1
Consider TLR5 for new therapeutic development against COVID-19.考虑将Toll样受体5（TLR5）用于抗2019冠状病毒病（COVID-19）的新治疗方法开发。
J Med Virol. 2020 Nov;92(11):2314-2315. doi: 10.1002/jmv.25997. Epub 2020 May 22.
2
Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: Analysis.针对 SARS-CoV-2 核衣壳磷蛋白 RNA 结合域的减毒亚单位疫苗设计：分析。
J Immunol Res. 2020 Sep 17;2020:2837670. doi: 10.1155/2020/2837670. eCollection 2020.
3
Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2.使用 SARS-CoV-2 的整个结构免疫原性表位设计 COVID-19 亚单位疫苗的免疫信息学
Sci Rep. 2020 Nov 30;10(1):20864. doi: 10.1038/s41598-020-77547-4.
4
Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An Analysis.基于 SARS-CoV-2 刺突蛋白的 COVID-19 多表位亚单位疫苗设计：分析。
J Immunol Res. 2020 Nov 19;2020:8893483. doi: 10.1155/2020/8893483. eCollection 2020.
5
Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country.鉴定 SARS-CoV-2 蛋白在南美的新型候选表位：按国家/地区分析 HLA 频率的综述。
Front Immunol. 2020 Sep 3;11:2008. doi: 10.3389/fimmu.2020.02008. eCollection 2020.
6
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.微针阵列递呈的重组冠状病毒疫苗：免疫原性和快速转化开发。
EBioMedicine. 2020 May;55:102743. doi: 10.1016/j.ebiom.2020.102743. Epub 2020 Apr 2.
7
3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics.基于 3CL 水解酶的 SARS-CoV-2 多表位肽疫苗：免疫信息学方法
J Med Virol. 2020 Oct;92(10):2114-2123. doi: 10.1002/jmv.25993. Epub 2020 May 22.
8
Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).基于免疫信息学设计针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的基于表位的亚单位疫苗。
Immunobiology. 2020 May;225(3):151955. doi: 10.1016/j.imbio.2020.151955. Epub 2020 May 11.
9
Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach.运用免疫信息学方法设计针对新兴冠状病毒病 2019（COVID-19）的多表位疫苗。
Front Immunol. 2020 Jul 10;11:1663. doi: 10.3389/fimmu.2020.01663. eCollection 2020.
10
Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine synthesis using immunoinformatics approach.运用免疫信息学方法挖掘严重急性呼吸综合征冠状病毒2基因组以用于基于表位的亚单位疫苗合成。
J Cell Physiol. 2021 Feb;236(2):1131-1147. doi: 10.1002/jcp.29923. Epub 2020 Jul 9.
引用本文的文献
1
Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients.新型冠状病毒肺炎治疗的药物基因组学研究：识别与新冠肺炎患者治疗反应相关的多态性
Biomedicines. 2025 Feb 21;13(3):553. doi: 10.3390/biomedicines13030553.
2
SARS-CoV-2 Omicron Spike shows strong binding affinity and favourable interaction landscape with the TLR4/MD2 compared to other variants.与其他变体相比，严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）奥密克戎变异株刺突蛋白与Toll样受体4（TLR4）/髓样分化蛋白2（MD2）表现出很强的结合亲和力和良好的相互作用态势。
J Genet Eng Biotechnol. 2024 Mar;22(1):100347. doi: 10.1016/j.jgeb.2023.100347. Epub 2024 Jan 22.
3
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
4
Identification of toll-like receptor 5 and acyl-CoA synthetase long chain family member 1 as hub genes are correlated with the severe forms of COVID-19 by Weighted gene co-expression network analysis.通过加权基因共表达网络分析鉴定 Toll 样受体 5 和酰基辅酶 A 合成酶长链家族成员 1 为与 COVID-19 严重形式相关的枢纽基因。
IET Syst Biol. 2023 Dec;17(6):327-335. doi: 10.1049/syb2.12079. Epub 2023 Oct 12.
5
Bioinformatics and system biology approach to identify the influences among COVID-19, ARDS and sepsis.生物信息学和系统生物学方法识别 COVID-19、ARDS 和脓毒症之间的影响。
Front Immunol. 2023 May 16;14:1152186. doi: 10.3389/fimmu.2023.1152186. eCollection 2023.
6
Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach. Toll 样受体在 SARS-CoV-2 中的作用：一种治疗方法。
Int J Mol Sci. 2022 Sep 14;23(18):10716. doi: 10.3390/ijms231810716.
7
Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity.新冠肺炎患者肠道微生物群模式的改变：炎症和疾病严重程度的标志物。
World J Gastroenterol. 2022 Jul 7;28(25):2802-2822. doi: 10.3748/wjg.v28.i25.2802.
8
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.SARS-CoV-2 及其具有逃逸突变的新兴变异株的免疫逃逸、抗体逃逸、部分疫苗逃逸的详细概述。
Front Immunol. 2022 Feb 9;13:801522. doi: 10.3389/fimmu.2022.801522. eCollection 2022.
9
Toll-Like Receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective.Toll 样受体（TLRs）作为治疗 SARS-CoV-2 的治疗靶点：免疫生物学视角。
Adv Exp Med Biol. 2021;1352:87-109. doi: 10.1007/978-3-030-85109-5_6.
10
TLRs in COVID-19: How they drive immunopathology and the rationale for modulation.TLRs 在 COVID-19 中的作用：它们如何驱动免疫病理以及调控的原理。
Innate Immun. 2021 Oct;27(7-8):503-513. doi: 10.1177/17534259211051364. Epub 2021 Nov 20.
本文引用的文献
1
Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.利用先天免疫来清除严重急性呼吸综合征冠状病毒2（SARS-CoV-2）并改善冠状病毒病（COVID-19）病情。
Physiol Genomics. 2020 May 1;52(5):217-221. doi: 10.1152/physiolgenomics.00033.2020. Epub 2020 Apr 10.
2
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.微针阵列递呈的重组冠状病毒疫苗：免疫原性和快速转化开发。
EBioMedicine. 2020 May;55:102743. doi: 10.1016/j.ebiom.2020.102743. Epub 2020 Apr 2.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病（COVID-19）患者免疫反应失调。
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
5
Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.基于表位的新型冠状病毒 2019（SARS-CoV-2）肽疫苗的研制：免疫信息学方法。
J Med Virol. 2020 Jun;92(6):618-631. doi: 10.1002/jmv.25736. Epub 2020 Mar 5.
6
Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir.Toll 样受体 5 激动剂鞭毛蛋白可独立于Ⅰ型干扰素和白细胞介素 22 减少甲型流感病毒复制，并提高奥司他韦的抗病毒疗效。
Antiviral Res. 2019 Aug;168:28-35. doi: 10.1016/j.antiviral.2019.05.002. Epub 2019 May 9.
7
TLR5: beyond the recognition of flagellin.Toll样受体5：超越鞭毛蛋白识别
Cell Mol Immunol. 2017 Dec;14(12):1017-1019. doi: 10.1038/cmi.2017.122. Epub 2017 Nov 20.
8
Frontline Science: Nasal epithelial GM-CSF contributes to TLR5-mediated modulation of airway dendritic cells and subsequent IgA response.前沿科学：鼻上皮细胞 GM-CSF 有助于 TLR5 介导的气道树突状细胞调节和随后的 IgA 反应。
J Leukoc Biol. 2017 Sep;102(3):575-587. doi: 10.1189/jlb.3HI0816-368RR. Epub 2017 May 18.
9
A conserved TLR5 binding and activation hot spot on flagellin.鞭毛蛋白上保守的 TLR5 结合和激活热点。
Sci Rep. 2017 Jan 20;7:40878. doi: 10.1038/srep40878.
10
Utilizing a TLR5-Adjuvanted Cytomegalovirus as a Lentiviral Vaccine in the Nonhuman Primate Model for AIDS.在艾滋病非人灵长类动物模型中，利用一种含Toll样受体5佐剂的巨细胞病毒作为慢病毒疫苗。
PLoS One. 2016 May 16;11(5):e0155629. doi: 10.1371/journal.pone.0155629. eCollection 2016.
Zotero 插件